Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
Eli Lilly and Co (NYSE: LLY) announced that its diabetes drug, Mounjaro, will be added to China's state-run health insurance scheme from January 1, 2026.
Eli Lilly offers a stable, growing dividend backed by exceptional profitability and solid financial health, making it a prime pick for long-term dividend growth investors.
JACKSONVILLE BEACH, Fla., Dec. 4, 2025 (SEND2PRESS NEWSWIRE) -- Industrial SalesLeads today announced the findings of its November 2025 report on planned capital project spending within the North American Industrial Manufacturing sector. The firm's research, which tracks new plant construction, facility expansions, and significant equipment modernization, identified 154 new projects. Capital project activity remains stable, with 154 new projects in November, nearly matching the 155 projects tracked in October.
Despite Agilent Technologies’ underperformance relative to its industry peers, Wall Street analysts remain moderately optimistic about the stock’s prospects.
As of late 2025, the financial markets are in the midst of a profound transformation, driven by the dynamic and often divergent interplay between institutional behemoths and an increasingly empowered army of retail investors. This evolving landscape is characterized by heightened volatility, new thematic rallies, and a significant blurring of
The U.S. stock market is currently navigating a period of cautious optimism, working to regain solid ground after a tumultuous year marked by significant losses in early 2025 and persistent concerns about valuation. While major indices have shown remarkable resilience, underlying economic headwinds and the evolving landscape of artificial
